Medivir scraps pancreatic cancer program; Ambrx recruits Amgen vet as new CMO;

@FierceBiotech: ICYMI yesterday: J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex. Report | Follow @FierceBiotech

@JohnCFierce: Catalent stops production at French plant, brings in law enforcement after it twice detects tampering. FiercePharma story | Follow @JohnCFierce

@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce

> Sweden's Medivir is scrapping its ADAM8 inhibitor program for pancreatic cancer. And its licensing agreement with Cancer Research Technology is being thrown out alongside the program. Release

> Ambrx, 6 months removed from being acquired by a group of Chinese drugmakers, has recruited Amgen ($AMGN) veteran Yong-Jiang Hei to serve as its chief medical officer. More

> The U.K.'s Cell Therapy Catapult has begun construction of its cell and gene therapy manufacturing center. Release

Medical Device News

@FierceMedDev: Crime syndicates are hacking devices to steal private medical information for profit. ICYMI last week | Follow @FierceMedDev

@EmilyWFierce: calling for more regulation of lab-developed tests prior to congressional hearing today. More from the WSJ | Follow @EmilyWFierce

> SI-Bone gets $39M+ in debt to market joint fusion implant system. Story

> FDA approves, Medtronic launches the first remote monitoring pacemaker app. Report

> Diagnostics companies jump into rapidly growing market for point-of-care superbug tests. Article

Pharma News

@FiercePharma: Indonesia's Kalbe and South Korea's Genexine link up for biomedical work. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: There are lots of changes going on among generics producers but here are the top players. Feature | Follow @EricPFierce

> J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price. Report

> Can Valeant win without big price hikes? Early Addyi scripts aren't a good sign. More

> U.S. lawmakers step up drug-pricing probes, add Valeant pharmacy to their target list. Article

Pharma Manufacturing News

> Top Novartis exec in India says two plants warned by FDA completing remediation. Item

> Baxter Singapore plant gets FDA OK to produce Advate hemophilia product. More

> Valeant adds recall to long list of problems. Article

> Regulator halts Catalent production at French plant where product sabotage suspected. Report

> Four Roche plants go up for sale in move to more high-potency, targeted drugs. Story

Drug Delivery News

> NC State team: Gold nanoparticles can control the shape of DNA, RNA. Report

> Avedro bags $32M in financing to expand use of its drug delivering ophthalmology platform. More

> Egalet announces patent for its abuse-deterrence platform. Item

> Swiss scientists take a look inside 'cubosomes' for drug delivery potential. Story

> RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. Article

Pharma Asia News

> Lee's Pharma affiliate licenses Tragara's TG02 oncology treatment for much of Asia. Story

> Indian drugmakers eye Japanese market for acquisitions. Report

> India looks to push development of biotech startups. More

> HK-based Chi-Med takes another regulatory step to Nasdaq listing. Article

> Australia's Mesoblast formally lists on Nasdaq. Item